Skip to content
Dr Amol Akhade· @SuyogCancer · X·· 23 hours agoScore90

durvalumab

Body

So no one knows why Durvalumab worked and Pembrolizumab and Nivo failed in perioperative MIBC trials. @DrChoueiri @tompowles1 @HHammersMD @montypal @OncoAlert @myESMO #esmo26

2038 views · 19 likes · 10 reposts · 3 replies

Conference abstracts
2879ROmatched by Rapid oral 1: Gastrointestinal tumour, upper digestive

Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial

https://esmocongress.esmo.org
4737ROmatched by Rapid oral 1: Genitourinary tumours, renal and urothelial

Durvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POT

https://esmocongress.esmo.org
LBA2matched by Presidential Symposium I

Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial

https://esmocongress.esmo.org
LBA26matched by Proffered paper 2: Breast cancer, early and advanced stage

Short-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial

https://esmocongress.esmo.org
LBA3matched by Presidential Symposium I

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org
LBA37matched by Proffered paper: Gynaecological cancers

Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud

https://esmocongress.esmo.org
引用@
Infographic to show the cross trial comparisons of 3 phase III perioperative IO trials in MIBC Only one is positive. Why ? I don't know. Looking forward towards full data of 2 negative trials on day 1 #esmo26 @myESMO
在 X 查看被引用的帖子

Source: Dr Amol Akhade · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org